(Q40531699)

21 September 2017

title

Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies (English)

1 reference

21 September 2017

1 reference

Moshe Mittelman

1

1 reference

21 September 2017

Aliza Zeidman

2

1 reference

21 September 2017

Pazit Kanter

3

1 reference

21 September 2017

Odelia Katz

4

1 reference

21 September 2017

Howard Oster

5

1 reference

21 September 2017

Debbora Rund

6

1 reference

21 September 2017

Drorit Neumann

7

1 reference

21 September 2017

publication date

1 March 2004

1 reference

European Journal of Haematology

21 September 2017

published in

1 reference

21 September 2017

volume

72

1 reference

21 September 2017

issue

3

1 reference

21 September 2017

page(s)

155-165

1 reference

Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00190.X

Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00190.X

Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00190.X

The effects of anemia in hematologic malignancies: more than a symptom

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00190.X

Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00190.X

Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00190.X

Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00190.X

Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00190.X

Expression of erythropoietin receptor splice variants in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00190.X

Erythropoietin regulates tumour growth of human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00190.X

The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00190.X

Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00190.X

HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00190.X

10.1046/J.0902-4441.2003.00190.X

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference